2021
High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases
Dai L, Li YH, Liang YY, Zhao J, Chen G, Yin J, Postmus PE, Addeo A, Blasberg JD, Onesti CE, Liao ZW, Rao XG, Long HD. High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastases. Journal Of Thoracic Disease 2021, 13: 2437-2446. PMID: 34012591, PMCID: PMC8107517, DOI: 10.21037/jtd-21-307.Peer-Reviewed Original ResearchNon-small cell lung cancer patientsCell lung cancer patientsBrain metastasesKaplan-Meier analysisNSCLC patientsLung cancer patientsCell adhesion molecule 2Overall survivalCox analysisPoor prognosisCancer patientsAffiliated Cancer HospitalHigh expressionIndependent risk factorSolid organ malignanciesOS of patientsCADM2 expressionLymph node metastasisTumor T stagePotential prognostic significanceGuangzhou Medical UniversityExpression levelsReal-time polymerase chain reactionQuantitative real-time polymerase chain reactionChi-square test
2019
OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3
Oezkan F, He K, Owen D, Pietrzak M, Cho J, Kitzler R, Pearson R, Rusch V, Chaft J, Suh R, Blasberg J, Reckamp K, Raz D, Kneuertz P, Fiorillo L, Garon E, Nicholas A, Johnson A, Schulze K, Grindheim J, Banchereau R, Phan S, Bunn P, Kwiatkowski D, Johnson B, Kris M, Wistuba I, Lee J, Lozanski G, Carbone D. OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3. Journal Of Thoracic Oncology 2019, 14: s242-s243. DOI: 10.1016/j.jtho.2019.08.482.Peer-Reviewed Original ResearchBenefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database.
Dendy Case M, Uhlig J, Blasberg J, Boffa D, Chiang A, Gettinger S, Kim H. Benefit of combining local treatment and systemic therapy for stage IV NSCLC: Results from the National Cancer Database. Journal Of Clinical Oncology 2019, 37: 8545-8545. DOI: 10.1200/jco.2019.37.15_suppl.8545.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer DatabaseStage IV non-small cell lung cancerStage IV NSCLC patientsSystemic therapyOverall survivalSurgical resectionPatient demographicsNSCLC patientsCancer DatabaseMultivariable Cox proportional hazards modelsSquamous cell carcinoma patientsPropensity scoreMultivariable logistic regression modelCox proportional hazards modelSuperior overall survivalCell carcinoma patientsCell lung cancerLung cancer treatmentProportional hazards modelLogistic regression modelsLimited nodalTA patientsMetastatic diseaseMultivariable adjustment
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients
2012
Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population
Joseph S, Harrington R, Walter D, Goldberg JD, Li X, Beck A, Litton T, Hirsch N, Blasberg J, Slomiany M, Rom W, Pass H, Donington J. Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. Cancer Biomarkers 2012, 12: 177-184. PMID: 23568008, PMCID: PMC3746829, DOI: 10.3233/cbm-130306.Peer-Reviewed Original ResearchConceptsIncident cancerPlasma osteopontinNon-small cell lung cancer careLung cancer careCase-control studySerial plasmaNSCLC patientsCT screeningSurveillance intervalsCancer careLung cancerPlasma levelsWilcoxon Signed Rank TestDisease statusCancerSigned Rank TestBenign nodulesSecreted phosphoproteinCTRank testOsteopontinEarly evidenceNSCLCPatientsNSCLCs
2009
Reduction of elevated plasma osteopontin levels with resection of non-small cell lung cancer (NSCLC)
Blasberg J, Pass H, Flores R, Donington J. Reduction of elevated plasma osteopontin levels with resection of non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2009, 27: 11019-11019. DOI: 10.1200/jco.2009.27.15_suppl.11019.Peer-Reviewed Original ResearchNon-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerEarly-stage NSCLC patientsStage NSCLC patientsPlasma osteopontin levelsNSCLC patientsOPN levelsPlasma OPNOsteopontin levelsIndependent cohortElevated Plasma Osteopontin LevelsStage I patientsImpact of surgeryCell lung cancerResectable NSCLC patientsSignificant decreaseNSCLC correlatesFormer smokersI patientsPrognostic significanceValidation cohortLung cancerPatientsMultivariate analysis